116 related articles for article (PubMed ID: 36288641)
21. Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway.
Shen C; Zhang Z; Tian Y; Li F; Zhou L; Jiang W; Yang L; Zhang B; Wang L; Zhang Y
BMC Med; 2021 Nov; 19(1):283. PubMed ID: 34819055
[TBL] [Abstract][Full Text] [Related]
22. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
[TBL] [Abstract][Full Text] [Related]
23. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
24. Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Toews K; Grunewald L; Schwiebert S; Klaus A; Winkler A; Ali S; Zirngibl F; Astrahantseff K; Wagner DL; Henssen AG; Deubzer HE; Schulte JH; Ochsenreither S; Eggert A; Künkele A
Mol Carcinog; 2020 Jul; 59(7):724-735. PubMed ID: 32333465
[TBL] [Abstract][Full Text] [Related]
25. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R
Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461
[TBL] [Abstract][Full Text] [Related]
26. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract][Full Text] [Related]
27. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
Yuti P; Wutti-In Y; Sawasdee N; Kongkhla K; Phanthaphol N; Choomee K; Chieochansin T; Panya A; Junking M; Yenchitsomanus PT; Sujjitjoon J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109442. PubMed ID: 36435066
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro.
Batchu RB; Gruzdyn OV; Mahmud EM; Chukr F; Dachepalli R; Manmari SK; Mostafa G; Weaver DW; Gruber SA
Surgery; 2018 Mar; 163(3):627-632. PubMed ID: 29336814
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
33. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth.
Qin L; Zhao R; Chen D; Wei X; Wu Q; Long Y; Jiang Z; Li Y; Wu H; Zhang X; Wu Y; Cui S; Wei W; Yao H; Liu Z; Cao S; Yao Y; Zhang Z; Li P
Biomark Res; 2020; 8():19. PubMed ID: 32514352
[TBL] [Abstract][Full Text] [Related]
34. A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis.
Ma Q; He X; Zhang B; Guo F; Ou X; Yang Q; Shu P; Chen Y; Li K; Gao G; Zhu Y; Qin D; Tang J; Li X; Jing M; Zhao J; Mo Z; Liu N; Zeng Y; Zhou K; Feng M; Liao W; Lei W; Li Q; Li D; Wang Y
Signal Transduct Target Ther; 2022 Nov; 7(1):380. PubMed ID: 36402752
[TBL] [Abstract][Full Text] [Related]
35. Mesothelin, a novel immunotherapy target for triple negative breast cancer.
Tchou J; Wang LC; Selven B; Zhang H; Conejo-Garcia J; Borghaei H; Kalos M; Vondeheide RH; Albelda SM; June CH; Zhang PJ
Breast Cancer Res Treat; 2012 Jun; 133(2):799-804. PubMed ID: 22418702
[TBL] [Abstract][Full Text] [Related]
36. Activation of Notch-1 signaling pathway in macrophages to secrete PD-L1 and regulate cytotoxicity of CAR-T cells in diffuse large B-cell lymphoma.
Li W; Wu L; Huang C; Ma H; Wang L; Liu W; Liu L
Aging (Albany NY); 2024 Jan; 16(2):1845-1859. PubMed ID: 38261741
[TBL] [Abstract][Full Text] [Related]
37. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis.
Qin L; Cui Y; Yuan T; Chen D; Zhao R; Li S; Jiang Z; Wu Q; Long Y; Wang S; Tang Z; Pan H; Li X; Wei W; Yang J; Luo X; Zhang Z; Tang Q; Liu P; Weinkove R; Yao Y; Qin D; Thiery JP; Li P
Nat Commun; 2022 Oct; 13(1):6051. PubMed ID: 36229619
[TBL] [Abstract][Full Text] [Related]
38. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
39. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors.
Wang Z; Li N; Feng K; Chen M; Zhang Y; Liu Y; Yang Q; Nie J; Tang N; Zhang X; Cheng C; Shen L; He J; Ye X; Cao W; Wang H; Han W
Cell Mol Immunol; 2021 Sep; 18(9):2188-2198. PubMed ID: 34381179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
